<code id='DD7B55F992'></code><style id='DD7B55F992'></style>
    • <acronym id='DD7B55F992'></acronym>
      <center id='DD7B55F992'><center id='DD7B55F992'><tfoot id='DD7B55F992'></tfoot></center><abbr id='DD7B55F992'><dir id='DD7B55F992'><tfoot id='DD7B55F992'></tfoot><noframes id='DD7B55F992'>

    • <optgroup id='DD7B55F992'><strike id='DD7B55F992'><sup id='DD7B55F992'></sup></strike><code id='DD7B55F992'></code></optgroup>
        1. <b id='DD7B55F992'><label id='DD7B55F992'><select id='DD7B55F992'><dt id='DD7B55F992'><span id='DD7B55F992'></span></dt></select></label></b><u id='DD7B55F992'></u>
          <i id='DD7B55F992'><strike id='DD7B55F992'><tt id='DD7B55F992'><pre id='DD7B55F992'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:23873
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In